Kevin Dunleavy is a Staff Writer at Herald-Mail Media. He covers a diverse range of themes including medicine and healthcare, finance, and legal affairs, with a particular focus on topics such as oncology, mental health care, and corporate finance. Kevin's work has been featured in notable publications including Yahoo Sports, Biotech, and Deadspin.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Kevin Dunleavy's coverage revolves around the healthcare and pharmaceutical industry, focusing on regulatory approvals, drug development, M&A activities, and legal settlements. His articles often cite data and press releases to support the information presented.
Given his focus on regulatory approvals and drug developments, Kevin may be interested in receiving pitches related to new drugs or treatments entering clinical trials or seeking FDA approval. Additionally, he might be interested in insights from experts who can provide analysis of pharmaceutical market trends supported by relevant data.
As Kevin's geographic focus is not specified but given the international nature of pharmaceutical companies' operations and regulations, sources with a global perspective on healthcare and pharmaceuticals are likely to resonate with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Kevin Dunleavy, Angus Liu, Fraiser Kansteiner
Welcome to Fierce Pharma's regulatory tracker for the second half of 2026.
By: Kevin Dunleavy
Contract manufacturing powerhouse Lonza is growing in more ways than one.
By: Kevin Dunleavy
Vertex has secured a label expansion through the FDA's Commis
By: Kevin Dunleavy
Vertex Pharmaceuticals has struck a $10 billion deal—its largest ever—to acquire Crinetics Pharmaceuticals.
Novartis is executing more layoffs at its U.S. headquarters in East Hanover, New Jersey, handing 322 employees pink slips.
By: Kevin Dunleavy
After thriving on the market for more than a decade as the only treatment for Dupuytrens contracture and Peyronie's disease, Keenova Therapeutics' Xiaflex has
By: Kevin Dunleavy
The surprising failure of AstraZeneca and Ionis in a key phase 3 trial of Wainua in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) has
By: Kevin Dunleavy
Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential boost in its competition with Johnson & Johnson's powerhouse Darzalex.
By: Kevin Dunleavy
Amid restructuring efforts, Bayer has addressed its need for a capital infusion in pharma under a deal
By: Kevin Dunleavy
In an initiative to increase the efficiency of drug manufacturing in the United States, the FDA has
